title: Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
abstract: BACKGROUND
  To evaluate the effect of Ozurdex® on intraocular pressure in patients with macular edema alone (group 1) or associated with glaucoma or ocular hypertension (group 2).
  
  
  METHODS
  A clinical, retrospective, observational, comparative study included 92 eyes with macular edema treated with a single injection of Ozurdex®; 27 eyes were previously diagnosed with glaucoma or ocular hypertension.
  
  
  RESULTS
  The mean intraocular pressure (group 1 vs. group 2) after injection was 12.1 versus 19.9 mm Hg, (p < 0.05; day 1); 17.5 versus 19.7 mm Hg (p < 0.05; month 1); 18.4 versus 20.9 mm Hg (p < 0.05; month 2); 15 versus 17.4 mm Hg (p < 0.05; month 3); 13.9 versus 16.7 mm Hg (p > 0.05; month 6); 13.8 versus 15.1 mm Hg (p > 0.05; month 9) and 13.1 versus 16.4 mm Hg (p > 0.05; month 12). Thirty eyes (32.6%) showed ocular hypertension (intraocular pressure >21 mm Hg) after the injection: 21.5% of group 1 and 59.3% of group 2. In group 2, 27 eyes (100%) needed medical treatment to reduce intraocular pressure in comparison to 8 patients (12.3%) in group 1 (p < 0.001).
  
  
  CONCLUSIONS
  Intravitreal injection of Ozurdex® was associated with ocular hypertension in 32.6% of the eyes. Previous glaucoma or ocular hypertension are risk factors for this increase.
authors.affiliation: Glaucoma Department, Instituto de Microcirugx00ED;a Ocular, Barcelona, Spain.
authors.forename: Stefania
authors.initials: S
authors.lastname: Mazzarella
authors.forename: Carlos
authors.initials: C
authors.lastname: Mateo
authors.forename: Silvia
authors.initials: S
authors.lastname: Freixes
authors.forename: Anniken
authors.initials: A
authors.lastname: Burés-Jelstrup
authors.forename: Jose
authors.initials: J
authors.lastname: Rios
authors.forename: Rafael
authors.initials: R
authors.lastname: Navarro
authors.forename: Jose
authors.initials: J
authors.lastname: García-Arumí
authors.forename: Borja
authors.initials: B
authors.lastname: Corcóstegui
authors.forename: Elena
authors.initials: E
authors.lastname: Arrondo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D004343:Drug Implants; D005260:Female; D005901:Glaucoma / Q000150:complications; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D012189:Retrospective Studies; D012307:Risk Factors; D014065:Tonometry, Ocular; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone